Cambium Bio Ltd
CMB
Company Profile
- Business description- Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. 
- Contact- Unit 2.06, 31 Lexington Drive 
 Bella VistaNSW2153
 AUS- T: +61 1300995098 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Biotechnology - Fiscal Year End- 30 June 2026 - Employees
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,206.70 | 32.80 | 0.36% | 
| CAC 40 | 8,147.35 | 53.53 | -0.65% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,721.06 | 35.08 | -0.36% | 
| HKSE | 26,282.69 | 63.45 | -0.24% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 51,325.61 | 17.96 | 0.04% | 
| NZX 50 Index | 13,498.36 | 39.07 | 0.29% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,913.20 | 33.20 | 0.37% | 
| SSE Composite Index | 3,986.90 | 29.43 | -0.73% |